Patients with myelodysplastic syndrome (MDS) in the treatment arm were more likely to achieve transfusion independence, but the difference vs placebo was not statistically significant. A new phase 3 ...
Credit: Getty Images. The approval was based on data from the pivotal phase 3 COMMANDS trial that compared luspatercept to epoetin alfa in 356 patients with anemia and lower-risk MDS. The Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback